Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anurag Relan

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Clinical Immunology (Orlando, Fla.)|November 19, 2024
A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysisV Koneti Rao, Anna Šedivá, Virgil A S H Dalm, et al.
Frontiers in Immunology|February 5, 2025
Piloting an automated query and scoring system to facilitate APDS patient identification from health systemsAmy M FitzPatrick, Aaron T Chin, Sharon Nirenberg, et al.
The Journal of Allergy and Clinical Immunology|June 21, 2016
Allergenicity and safety of recombinant human C1 esterase inhibitor in patients with allergy to rabbit or cow's milkMignon T van den Elzen, Harmieke van Os-Medendorp, Heike Röckmann-Helmbach, et al.
The Journal of Allergy and Clinical Immunology|October 5, 2023
Interim analysis: Open-label extension study of leniolisib for patients with APDSV Koneti Rao, Elaine Kulm, Anna Šedivá, et al.
Blood|November 18, 2022
A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndromeV Koneti Rao, Sharon Webster, Anna Šedivá, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Clinical Immunology (Orlando, Fla.)|November 19, 2024
A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysisV Koneti Rao, Anna Šedivá, Virgil A S H Dalm, et al.
Frontiers in Immunology|February 5, 2025
Piloting an automated query and scoring system to facilitate APDS patient identification from health systemsAmy M FitzPatrick, Aaron T Chin, Sharon Nirenberg, et al.
The Journal of Allergy and Clinical Immunology|June 21, 2016
Allergenicity and safety of recombinant human C1 esterase inhibitor in patients with allergy to rabbit or cow's milkMignon T van den Elzen, Harmieke van Os-Medendorp, Heike Röckmann-Helmbach, et al.
The Journal of Allergy and Clinical Immunology|October 5, 2023
Interim analysis: Open-label extension study of leniolisib for patients with APDSV Koneti Rao, Elaine Kulm, Anna Šedivá, et al.
Blood|November 18, 2022
A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndromeV Koneti Rao, Sharon Webster, Anna Šedivá, et al.
Pageof 4